

Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

<https://marketpublishers.com/r/B459123CA76EN.html>

Date: October 2018

Pages: 152

Price: US\$ 3,000.00 (Single User License)

ID: B459123CA76EN

Abstracts

This report can be delivered to the clients within 48 hours

'Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 30+ products along with 25+ companies involved. Acerta Pharma and BeiGene are developing therapeutic drugs in the higher phase and Acerta Pharma has been granted both Orphan and Breakthrough Therapy Designation from FDA.

Products covered by Phase

Filed, Phase III, Phase II and Phase I

IND and Pre-clinical

Overview of pipeline development activities for Bruton's Tyrosine Kinase (BTK) Inhibitors

Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Bruton's Tyrosine Kinase (BTK) Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Bruton's Tyrosine Kinase (BTK) Inhibitors

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Bruton's Tyrosine Kinase (BTK) Inhibitors and also provide company profiling

Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario Bruton's Tyrosine Kinase (BTK) Inhibitors to formulate effective R&D strategies

Assess challenges and opportunities that influence Bruton's Tyrosine Kinase (BTK) Inhibitors R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline depth and focus of target therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Bruton's Tyrosine Kinase (BTK) Inhibitors to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based

Decisions

Contents

- Report Highlights
- Executive Summary
- Collaborations
- Technology
- Overview
- Structure of Bruton's Tyrosine Kinase
- Mechanism of Action
- Expression of BTK
- BTK Mutations
- Bruton's Tyrosine Kinase Inhibitor
- BTK Inhibitors Role in Oncology
- BTK Inhibitors Role in Autoimmune Diseases
- Competitive Landscape – Active Drugs
- Marketed and Pipeline Drugs
- Marketed Drugs
- Imbruvica: Janssen
- Product Description
- Research and Development
- Product Development Activities
- Drug Sales
- Imbruvica – Heat Map
- Analyst Insights: Imbruvica
- Competitive landscape for Imbruvica
- Sales of Imbruvica
- Clinical Future of Imbruvica
- BTK Inhibitors Market Evolution
- BTK Inhibitors Class Share Evolution
- Pipeline Therapeutics (Active Products)
- Comparative Analysis
- Late Stage Products (Filed & Phase III)
- Comparative Analysis
- ACP-196: Acerta Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug Sales
- (The list continues)

Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Stage and Molecule Type
Inactive Products
Other Inactive Products
Gist of BTK Inhibitors
List of Product
List of companies
Appendix

List Of Tables

LIST OF TABLES

Table 1: Marketed and Pipeline BTK Inhibitors

Table 2: Total Products for BTK Inhibitors

Table 3: Late Stage Products (Phase III)

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I and IND)

Table 6: Pre-clinical Stage Products

Table 7: Assessment by Monotherapy Products

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Stage and Molecule Type

Table 11: List of Dormant Products

Table 12: Other Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1: Structure of Bruton's Tyrosine Kinase
- Figure 2: Involvement of BTK in B cell receptor signaling
- Figure 3: Marketed and Pipeline BTK Inhibitors
- Figure 4: Market Evolution (2013-2022)
- Figure 5: Total Products for BTK Inhibitors
- Figure 6: Late Stage Products (Filed & Phase III)
- Figure 7: Mid Stage Products (Phase II)
- Figure 8: Early Stage Products (Phase I and IND)
- Figure 9: Pre-clinical Stage Products
- Figure 10: Assessment by Monotherapy Products
- Figure 11: Assessment by Route of Administration
- Figure 12: Assessment by Stage and Route of Administration
- Figure 13: Assessment by Stage and Molecule Type

I would like to order

Product name: Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

Product link: <https://marketpublishers.com/r/B459123CA76EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B459123CA76EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

